Piper Jaffray analyst David Amsellem says he would not interpret the absence of an Ingrezza guidance range as suggestive of a more challenging outlook for Neurocrine Biosciences. "Quite the contrary," the analyst continues to believe the size of the underlying tardive dyskinesia population and "relatively favorable" payer landscape point to "ample room for continued aggressive Ingrezza sales growth." Amsellem reiterates an Overweight rating Neurocrine Biosciences and lowered his price target for the shares to $105 from $113 owing primarily to higher operating expense estimates.